The B4GALT1 Knockout 143B Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 143B human osteosarcoma cell line. This product features targeted disruption of the B4GALT1 gene through CRISPR/Cas9-mediated genome editing, yielding a heterogeneous pool of cells with loss-of-function mutations in the B4GALT1 locus. Unlike clonal isolates, this polyclonal format preserves the genetic diversity of the edited population, allowing researchers to study pooled knockout effects without single-cell bottleneck artifacts. The cells are supplied as a ready-to-use culture, suitable for immediate expansion and downstream experimentation in glycosylation biology and cancer research.
The 143B host cell line originates from a human osteosarcoma and is widely employed in cancer biology, particularly in studies of tumor progression and metastasis. This adherent, bone-derived cancerous line displays aggressive growth characteristics and has been extensively characterized for xenograft models and in vitro invasion assays. Its mesenchymal phenotype and robust proliferation make it an ideal platform for examining the contributions of glycosyltransferases to malignant behavior. The 143B background provides a clinically relevant context for dissecting B4GALT1-mediated pathways in a tumorigenic setting.
B4GALT1 encodes a Golgi-resident beta-1,4-galactosyltransferase that catalyzes the transfer of galactose from UDP-galactose to terminal N-acetylglucosamine residues on nascent glycoproteins and glycolipids. This galactosylation step is pivotal in N-glycan and O-glycan biosynthesis, glycosphingolipid maturation, and lactose synthesis in the mammary gland when complexed with alpha-lactalbumin. Upstream, B4GALT1 expression is regulated by the transcription factor SP1 and responds to cytokine stimulation, while its activity depends on UDP-galactose availability and Golgi trafficking chaperones. Downstream targets include galactosylated glycans that influence cell adhesion signaling, immune recognition, and extracellular matrix interactions, linking B4GALT1 to fundamental processes in cellular communication.
In the context of osteosarcoma, B4GALT1 knockout disrupts the synthesis of galactosylated glycoconjugates that are often aberrantly expressed in cancer cells. These glycan structures modulate integrin-mediated adhesion, cell migration, and metastatic dissemination. Loss of B4GALT1 in 143B cells is expected to alter surface glycoprotein and glycolipid profiles, potentially impairing invasive capacity and interactions with the microenvironment. This model thus serves as a powerful tool for uncovering glycosylation-dependent mechanisms that drive osteosarcoma pathology, offering insights into how glycan remodeling contributes to disease progression and immune evasion.
This knockout polyclonal population supports a broad range of research applications. It is particularly suited for glycosylation profiling using lectin blotting or flow cytometry, cell adhesion and migration assays, glyco-engineering studies, and immune cell interaction experiments. The heterogeneous knockout pool allows assessment of B4GALT1 function without clonal bias, complemented by confirmation via Western blotting and mass spectrometry-based glycomics. Researchers can employ these cells to screen for phenotypic changes in metastasis models or to validate glycosyltransferase targets in cancer. For further information, please contact Ascent Research.
